Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Pharmaceutical Group, a developer of proprietary pharmaceuticals in China, has received the State Food and Drug Administration (SFDA) approval for its Iguratimod drug - Iremod.
Subscribe to our email newsletter
The drug is designed to treat active rheumatoid arthritis and comes under a category of disease modifying anti-rheumatic drugs (DMARDS).
The clinical studies demonstrate that Iremod can relieve symptoms caused by active rheumatoid arthritis.
Simcere Pharmaceutical Group chairman and CEO Ren Jinsheng said they will continue to put their efforts and resources into developing and producing medicines for patients.